Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors-A Phase I Study

NCT04400851 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04400851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors-A Phase I Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Unknown status
Start date
August 11, 2020
Completion date
December 10, 2021
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric cancer